Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma

Journal of Immunotherapy

Volumn 37, Issue 7, 2014, Pages 360-365

  Lam, Elaine T ^a,h   Wong, Michael K K ^c,d   Agarwal, Neeraj ^e   Redman, Bruce G ^f   Logan, Theodore ^g   Gao, Dexiang ^b   Flaig, Thomas W ^a   Lewis, Karl ^a   Poust, Jamie ^b   Monk, Paul ^h   Jarkowski, Anthony ^d   Sendilnathan, Arun ^e   Bolden, Marcus ^g   Kuzel, Timothy M ⁱ   Olencki, Thomas ^h  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

high dose interleukin 2; renal cell carcinoma; sorafenib; sunitinib; tyrosine kinase inhibitor (TKI)

Indexed keywords

INTERLEUKIN 2; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART STRESS; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84906099224     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000044     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29
2. Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer. 2008;6(suppl 1):S7-S13
3. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696
4. Fisher RI, Rosenberg SA, Fyfe G. Long-Term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57
5. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293-301
6. McDermott DF, Ghebremichael M, Signoretti S, et al. The high-dose aldesleukin (HD IL-2) Select trial in patients with metastatic renal cell carcinoma (mRCC): Preliminary assessment of clinical benefit. J ClinOncol. 2010;28:15s, (suppl; abstr 4514
7. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124
9. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590
10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356: 125-134
11. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet. 2011; 378:1931-1939
12. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552-562
13. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28:475-480
14. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512
15. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGFtargeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009;32:181-185
16. Gotto AM Jr, Kuller LH. Eligibility for lipid-lowering drug therapy in primary prevention: How do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?. Circulation. 2002;105:136-139
17. Expert Panel Recommendations. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497
18. Expert Panel Recommendations. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421
19. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007;116:1971-1996
20. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50-e103
21. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol. 2002;20:2376-2381
22. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463
23. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-Targeted agents: Results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216
25. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-Term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996;14:2410-2411
26. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141
27. Shablak A, Sikand K, Shanks JH, et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother. 2011;34:107-112
28. Hawkins RE, Galvis V, Shanks J, et al. Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy. J Clin Oncol. 2012;30:(suppl 5; abstr 439
29. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA. 2007;297:611-619
30. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187
31. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019
32. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500-2508
33. Mego M, Reckova M, Obertova J, et al. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol. 2007;18:1906-1907
34. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19:1613-1618
35. Chintalgattu V, Rees ML, Culver JC, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5: 187ra69
36. WongMK, Kaufman HL, MorseM, et al. The transient nature of significant toxicities associated with high dose interleukin (HD IL-2): Preliminary data from the Proclaim study. (Abstract from the 27th Annual Scientific Meeting of the Society of Immunotherapy of Cancer). J Immunother. 2012;35:753
37. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366:2517-2519
38. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454
39. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-830
40. Amin A, Dudek A, Logan T, et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J Clin Oncol. 2013;31:(suppl 6; abstr 357